Top Neurology Research Papers

Overall: A strong meta-analysis of randomized trials demonstrates meaningful functional improvement from imaging-selected extended-window thrombolysis, although increased symptomatic hemorrhage and the need for advanced stroke workflows temper the net benefit.

Overall: A well-conducted randomized trial found a large improvement in 90-day functional independence using a feasible, reperfusion-guided blood pressure strategy, with no evident increase in major safety outcomes.

Overall: This large, rigorous trial found a modest but clinically meaningful reduction in recurrent ischemic stroke without a demonstrated increase in major bleeding, making the findings likely to influence secondary prevention practice.

Overall: A well-designed phase 3 trial found a very large, clinically important reduction in NMOSD relapse without an observed increase in severe treatment-related adverse events, though the small cohort, limited follow-up, and infusion burden reduce certainty and practicality.

Overall: Two consistent randomized phase 3 trials show large short-term improvements across important narcolepsy symptoms, tempered by very frequent adverse effects and limited long-term evidence.

Overall: A strong randomized trial found a clinically meaningful reduction in recurrent stroke with a practical single-pill regimen, offset by substantially more treatment discontinuation and limited applicability beyond intracerebral-hemorrhage survivors.

Overall: A pragmatic multicenter randomized comparison suggests a clinically meaningful neurological benefit from liberal transfusion in TBI, but the fragile, borderline result from a secondary analysis limits confidence and immediate practice-changing force.

Overall: Breastfeeding and Neurodevelopmental Outcomes in Children of Women Taking Antiseizure Medications provides clinically meaningful long-term reassurance from a prospective multicenter cohort, although residual confounding and limited subgroup precision prevent firm causal conclusions.

Overall: This uncontrolled but informative five-year extension reports substantial survival, respiratory, feeding, and motor benefits with no new safety signal, while its small selected cohort and lack of a comparator limit causal certainty and independent practice-changing impact.

Overall: Fixed-Dose Tavapadon for Early Parkinson Disease: A Randomized Clinical Trial — A strong phase 3 trial found substantial short-term motor and functional improvement with convenient dosing, but specialty involvement, common adverse effects, limited patient-reported results, and the absence of an active comparator constrain immediate primary-care impact.